GSK resubmits BLA for Cervarix
Executive Summary
Finally responding to a December 2007 "complete response" letter from FDA, GlaxoSmithKline has re-filed its BLA for Cervarix, its vaccine to prevent cervical cancer and pre-cancer related to human papillomavirus types 16 and 18. Cervarix is approved in Europe and is the market leader in the U.K., ahead of Merck's competing vaccine, Gardasil. GSK's new filing, announced March 30, includes final data from the pivotal HPV-008 study - the previous BLA was based upon interim data. Also holding up FDA approval was the fact that the vaccine uses an adjuvant that is new and has a new active ingredient for which the agency had no regulatory framework (1"The Pink Sheet" DAILY, Oct. 22, 2008)
You may also be interested in...
Glaxo Boasts Cervarix Protects Against Five Most Common HPV Strains
Yet another missive has been fired in the HPV vaccine wars. A new study finds that GlaxoSmithKline's Cervarix vaccine offers protection against five of the most common strains of human papillomarvirus that can lead to cervical cancer
GlaxoSmithKline Looks To Revamp U.S. Operations In Tough Environment
U.S. sales fell 13 percent in the third quarter due to generic competition and Avandia.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.